

COMPETITIVE TECHNOLOGIES INC
Form 10-Q
November 14, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2011

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 1-8696

COMPETITIVE TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

www.competitivetech.net

Delaware

36-2664428

Edgar Filing: COMPETITIVE TECHNOLOGIES INC - Form 10-Q

(State or other jurisdiction of incorporation or organization)

(I. R. S. Employer Identification No.)

1375 Kings Highway East, Suite 400 Fairfield,
Connecticut
(Address of principal executive offices)

06824
(Zip Code)

(203) 368-6044
(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.

Yes

No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "accelerated filer, large accelerated filer and smaller reporting company" as defined in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company)

Accelerated filer
Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act).

Yes

No

The number of shares of the registrant's common stock outstanding as of November 14, 2011 was 14,319,289 shares.

COMPETITIVE TECHNOLOGIES, INC.

INDEX TO QUARTERLY REPORT ON FORM 10-Q

PART I.	FINANCIAL INFORMATION	Page No.
Item 1.	Condensed Consolidated Interim Financial Statements (unaudited)	
	Condensed Consolidated Balance Sheets at September 30, 2011 and December 31, 2010 (unaudited)	3
	Condensed Consolidated Statements of Operations for the three months ended September 30, 2011 and three months ended October 31, 2010 (unaudited)	4
	Condensed Consolidated Statements of Operations for the nine months ended September 30, 2011 and nine months ended October 31, 2010 (unaudited)	5
	Condensed Consolidated Statement of Changes in Shareholders' Interest for the nine months ended September 30, 2011 (unaudited)	6
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2011 and nine months ended October 31, 2010 (unaudited)	7-8
	Notes to Condensed Consolidated Interim Financial Statements (unaudited)	9-20
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	21-29
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29
Item 4.	Controls and Procedures	29
PART II.	OTHER INFORMATION	
Item 1.	Legal Proceedings	30
Item 1A.	Risk factors	30
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30
Item 3.	Defaults Upon Senior Securities	30
Item 5.	Other Information	30
Item 6.	Exhibits	30

Signatures	31
Exhibit Index	32

PART I. FINANCIAL INFORMATION**Item 1. Condensed Consolidated Interim Financial Statements****COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES**

Condensed Consolidated Balance Sheets (Unaudited)

	September 30, 2011	December 31, 2010
Assets		
Current Assets:		
Cash and cash equivalents	\$	\$
	34,807	557,018
Restricted cash	750,000	750,000
Receivables, net of allowance of \$101,154 at September 30, 2011, and December 31, 2010	361,190	25,002
Due from Factor	465,000	-
Inventory, Finished Goods	4,230,156	1,729,929
Prepaid expenses and other current assets	72,583	77,952
Total current assets	5,913,736	3,139,901
Property and equipment, net	28,855	40,642
Security deposits	17,275	15,000
TOTAL ASSETS	\$	\$
	5,959,866	3,195,543
Liabilities and Shareholders' Interest (Deficit)		
Current Liabilities:		
Accounts payable, general	\$	\$
	1,009,384	148,457
Accounts payable, GEOMC	4,081,177	1,106,250
Accrued expenses and other liabilities	685,952	407,123
Notes payable	150,000	-
Derivative liability	67,781	132,353
Preferred stock liability	375,000	750,000
Total Current Liabilities	6,369,294	2,544,183
Commitments and Contingencies	-	-
Shareholders' interest (Deficit):		
5% preferred stock, \$25 par value, 35,920 shares authorized, 2,427 shares issued and outstanding	60,675	60,675
Series B preferred stock, \$0.001 par value, 20,000 shares authorized, no shares issued and outstanding	-	-

Series C convertible preferred stock, \$1,000 par value, 750 shares authorized, 375 shares issued and outstanding at September 30, 2011, and 750 shares issued and outstanding at December 31, 2010	-	-
Common stock, \$.01 par value, 20,000,000 shares authorized, 14,319,289 shares issued and outstanding at September 30, 2011 and 13,824,944 shares issued and outstanding at December 31, 2010	143,192	138,249
Capital in excess of par value	44,239,818	43,484,989
Receivable from Crisnic	-	(22,500)
Accumulated deficit	(44,853,113)	(43,010,053)
Total shareholders' interest (Deficit)	(409,428)	651,360
TOTAL LIABILITIES AND SHAREHOLDERS' INTEREST (DEFICIT)	5,959,866	3,195,543

\$

See accompanying notes

PART I. FINANCIAL INFORMATION (Continued)**COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES**

Condensed Consolidated Statements of Operations

(Unaudited)

	Three months ended September 30, 2011	Three months ended October 31, 2010
Revenue		
Product sales	\$	\$
	1,198,230	107,996
Cost of product sales	504,988	18,191
Gross profit from product sales	693,242	89,805
Other Revenue		
Retained royalties	4,322	7,464
Investment income	-	10
Other income	9,486	4,000
Total other revenue	13,808	11,474
Expenses		
Selling expenses	219,029	56,452
Personnel and consulting expenses	430,778	504,340
General and administrative expenses	601,055	633,205
Interest expense	9,002	1,695
Unrealized gain on derivative instrument	(15,149)	-
Total Expenses	1,244,715	1,195,692
Income (loss) before income taxes	(537,665)	(1,094,413)
Provision (benefit) for income taxes	-	-
Net income (loss)	\$	\$
	(537,665)	(1,094,413)
Basic income (loss) per share	\$	\$

		(0.04)	(0.08)
Basic weighted average number of common shares outstanding:		14,255,351	13,824,944
Diluted income (loss) per share	\$	(0.04)	\$ (0.08)
Diluted weighted average number of common shares outstanding:		14,255,351	13,824,944
	<i>See accompanying notes</i>		

PART I. FINANCIAL INFORMATION (Continued)**COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES**

Condensed Consolidated Statements of Operations

(Unaudited)

	Nine months ended September 30, 2011	Nine months ended October 31, 2010
Revenue		
Product sales	\$	\$
	3,336,506	1,673,671
Cost of product sales	1,483,862	524,767
Gross profit from product sales	1,852,644	1,148,904
Other Revenue		
Gain on sale of rental assets	34,728	-
Retained royalties	20,244	38,167
Investment income	-	35
Other income	30,625	4,800
Total other revenue	85,597	43,002
Expenses		
Selling expenses	416,123	286,920
Personnel and consulting expenses	1,204,288	1,498,487
General and administrative expenses	2,114,537	1,703,388
Interest expense	28,992	5,229
Unrealized loss on derivative instrument	17,361	-
Total Expenses	3,781,301	3,494,024
Income (loss) before income taxes	(1,843,060)	(2,302,118)
Provision (benefit) for income taxes	-	-
Net income (loss)	\$	\$
	(1,843,060)	(2,302,118)
Basic income (loss) per share	\$	\$

		(0.13)	(0.19)
Basic weighted average number of common shares outstanding:		13,994,740	12,232,955
Diluted income (loss) per share	\$		\$
		(0.13)	(0.19)
Diluted weighted average number of common shares outstanding:		13,994,740	12,232,955
	<i>See accompanying notes</i>		

PART I. FINANCIAL INFORMATION (Continued)**COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES**

Condensed Consolidated Statement of Changes in Shareholders' Interest (Deficit)

For the Nine Months Ended September 30, 2011

(Unaudited)

	Preferred Stock		Common Stock			Accumulated	Total
	Shares	Shares	Capital	Receivable	shareholders		
	outstanding	Amount outstanding	Amount	in excess	from	deficit	interest(deficit)
				of par	Crisnic		
				value	Fund		
Balance	2,427	\$ 13,824,944	\$	\$	\$	\$	
December 31, 2010		60,675	138,249	43,484,989	(22,500)	(43,010,053)	651,360
Net income (loss)						(1,843,060)	(1,843,060)
Common shares issued from the exercise of stock option grants	-	-	10,000	100	9,950	-	10,050
Return of shares issued to Crisnic	-	-	(25,000)	(250)	(22,250)	22,500	-
Common shares issued to settle accounts payable, general and accrued expenses	-	-	175,000	1,750	215,100	-	216,850
Conversion of Series C Convertible Preferred Stock	-	-	315,126	3,151	453,782	-	456,933
Common stock issued to directors	-	-	19,219	192	30,608	-	30,800

Compensation expense from stock option grants	-	-	-	-	67,639	-	67,639
Balance	\$		\$	\$	\$	\$	\$
September 30, 2011	2,427	60,675	14,319,289	143,192	44,239,818	-	(44,853,113)
							(409,428)
							<i>See accompanying notes</i>

PART I. FINANCIAL INFORMATION (Continued)**COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES**

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine months ended September 30, 2011	Nine months ended October 31, 2010
Cash flows from operating activities:		
Net income (loss)	\$	\$
	(1,843,060)	(2,302,118)
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Depreciation and amortization	17,400	40,826
Deferred rent	-	(14,180)
Share-based compensation - stock options	67,639	17,887
Share-based compensation - common stock	17,800	(2,225)
Accrued stock contribution (directors stock exp)	7,717	9,920
Gains on sale of rental assets	(34,728)	-
Unrealized loss on derivative instrument	17,361	-
Changes in assets and liabilities:		
Receivables	(336,188)	(527,806)
Due from factor	(465,000)	-
Prepaid expenses and other current assets	5,369	33,012
Inventory	(2,500,227)	179,074
Accounts payable, accrued expenses and other liabilities	4,336,816	449,260
Net cash (used in) operating activities	(709,101)	(2,116,350)
Cash flows from investing activities:		
Purchase of property and equipment	(14,685)	(18,580)
Proceeds from sale of rental asset	43,800	-
Increase in security deposits	(2,275)	-
Net cash provided by (used in) provided by investing activities	26,840	(18,580)
Cash flows from financing activities:		
Proceeds from sale of stock	-	2,066,478
Financing costs	-	(140,112)
Proceeds from note payable	200,000	-
Repayment of note payable	(50,000)	-
Proceeds from exercise of stock options	10,050	-
Cash provided by financing activities	160,050	1,926,366

Net (decrease) in cash and cash equivalents		(522,211)		(208,564)
Cash and cash equivalents at beginning of period		557,018		1,081,328
Cash and cash equivalents at end of period	\$		\$	
		34,807		872,764
Supplemental Cash Flow Information:				
Cash paid for interest	\$			-
		19,562		

Supplemental disclosure of non-cash transactions:

During August 2011, the company issued 100,000 common shares at \$1.25 per share to settle \$125,000 accrued liabilities.

During August 2011, the company issued 9,219 common shares at \$1.4103 per share to two of its directors in lieu of \$13,000 of directors' fees.

During June 2011, the Company converted 375 shares of Class C Convertible Preferred Stock to 315,126 shares of common stock at the conversion price of \$1.19 per share of common stock. In addition, \$81,933 of derivative liability was reclassified to equity upon conversion.

During May 2011, the Company issued 50,000 common shares at \$1.31 per share to settle \$65,600 of accrued liabilities.

During February 2011, the Company canceled 10,000 common shares previously issued to Crisnic and canceled the related \$9,000 receivable.

During February 2011, the Company issued 10,000 common shares at \$0.99 per share to settle \$9,900 of deferred payroll.

During January 2011, the Company canceled 15,000 common shares previously issued to Crisnic and canceled the related \$13,500 receivable.

During January 2011, the Company issued 15,000 common shares at \$1.09 per share to settle \$16,350 of accrued liabilities.

During the nine months ended October 31, 2010, we incurred \$140,112 of costs (including legal and auditing fees, exchange listing fees, and due diligence costs) related to our equity financing agreement with Crisnic Fund S.A. which were charged to Capital in Excess of Par Value.

During the nine months ended October 31, 2010, we amortized \$137,134 of deferred financing costs related to our equity financing agreement against Capital in Excess of Par Value.

See accompanying notes

Page 8

PART I. FINANCIAL INFORMATION (Continued)

COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Interim Financial Statements

(Unaudited)

1.

BASIS OF PRESENTATION

The interim condensed consolidated financial information presented in the accompanying condensed consolidated financial statements and notes hereto is unaudited.

Competitive Technologies, Inc. ("CTTC") and its majority-owned subsidiary, Vector Vision, Inc. ("VVI"), (collectively, "we" or "us") provide patent and technology licensing and commercialization services throughout the world, with concentrations in the U.S., Europe and Asia, with respect to a broad range of life and physical sciences, electronics, and nanotechnologies originally invented by individuals, corporations and universities.

On November 15, 2010, the Board of Directors of CTTC approved a fiscal year-end change from October 31 to December 31, in order to align its fiscal periods with the calendar year. We filed a Transitional Report on Form 10-Q for the two and five months ended December 31, 2010, and began a new fiscal year on January 1, 2011. CTTC will subsequently file its quarterly and annual reports for the new fiscal years ending December 31. CTTC's annual report on Form 10-K for the fiscal year ending December 31, 2011 will include separate audited financial statements for the five-month transitional period.

During the transitional period ended December 31, 2010, the Company dissolved its wholly owned subsidiary, CTT Trading Company, LLC and absorbed all of its functions. These consolidated financial statements include the accounts of CTTC and VVI. Inter-company accounts and transactions have been eliminated in consolidation.

We believe we made all adjustments necessary, consisting only of normal recurring adjustments, to present the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. The results for the three and nine months ended September 30, 2011 are not necessarily indicative of the results that can be expected for the next full fiscal year ending December 31, 2011.

The interim unaudited condensed consolidated financial statements and notes thereto, should be read in conjunction with our Annual Report on Form 10-K for the year ended July 31, 2010, filed with the Securities and Exchange Commission ("SEC") on October 27, 2010.

During the three and nine months ended September 30, 2011, and the three and nine months ended October 31, 2010, we had a significant concentration of revenues from our Calmare[®] pain therapy medical device. The percentages of gross revenue attributed to sales and rentals of Calmare[®] devices were 98% and 98% in the three and nine months ended September 30, 2011, respectively. The percentages of gross revenue attributed to sales and rentals of Calmare[®] devices were 94% and 97% in the three and nine months ended October 31, 2010, respectively. We continue to expand our sales activities for the Calmare[®] device and expect the majority of our revenues to come from this technology for at least the next two fiscal years. However, we continue to seek revenue from new or existing technologies or products to mitigate the concentration of revenues, and replace revenues from expiring licenses and patents on other technologies.

The Company incurred operating losses for the past two quarters, having produced marginal net income in the first quarter of 2011, after having incurred operating losses each quarter since fiscal 2006. The Company has taken steps to significantly reduce its operating expenses going forward and expects revenue from sales of Calmare[®] medical devices to grow. During the five month transitional period ended December 31, 2010; the Company undertook a major reduction of its operating expenses through staff reductions and reduced office space costs. The reduction continues to be implemented partially offset by certain legal costs. However, even at the reduced spending levels, should the anticipated increase in revenue from sales of Calmare[®] devices not occur the Company may not have sufficient cash flow to fund

operating expenses beyond the first quarter of calendar 2012. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include adjustments to reflect the possible future effect of the recoverability and classification of assets or amounts and classifications of liabilities that may result from the outcome of this uncertainty.

The Company's continuation as a going concern is dependent upon its developing recurring revenue streams sufficient to cover operating costs. The company does not have any significant individual cash or capital requirements in the budget going forward. If necessary, CTTC will meet anticipated operating cash requirements by further reducing costs, and/or pursuing sales of certain assets and technologies while we pursue licensing and distribution opportunities for our remaining portfolio of technologies. There can be no assurance that the Company will be successful in such efforts. Failure to develop a recurring revenue stream sufficient to cover operating expenses would negatively affect the Company's financial position.

Our liquidity requirements arise principally from our working capital needs, including funds needed to sell our current technologies and obtain new technologies or products, and protect and enforce our intellectual property rights, if necessary. We fund our liquidity requirements with a combination of cash on hand, cash flows from operations, if any, including royalty legal awards, short term borrowing, and sales of common stock. At September 30, 2011, we had no outstanding long-term debt.

During the three months ended September 30, 2011, the Company entered into a Factoring Agreement with Versant Funding, LLC ("Versant") to accelerate receivable collection and better manage cash flow. Under the Factoring Agreement the Company will sell to Versant certain of the Company's accounts receivables. For those accounts receivable the Company tenders to Versant and Versant chooses to purchase, Versant will advance 75% of the face value to the Company, and will submit a percentage of the remainder to the Company upon collection on the account. The percentage is based on the time it takes Versant to collect on the account. As part of the Factoring Agreement, the Company and Versant entered into a Security Agreement whereby the Company granted Versant a security interest in certain of the Company's assets to secure the Company's performance of the representations made with respect to the purchase of the accounts receivable. At September 30, 2011, due from factor of \$465,000 is made up of \$615,000 assigned to the factor and \$150,000 advances from the factor.

Sales of our Calmare® pain therapy medical device continue to be the major source of revenue for the Company. The Company acquired the exclusive, worldwide rights to the "Scrambler Therapy" technology in 2007. The Company's agreement with Giuseppe Marineo, the inventor of "Scrambler Therapy" technology, and Delta Research and Development ("Delta"), authorizes CTTC to manufacture and sell worldwide the device developed from the patented "Scrambler Therapy" technology. The "Scrambler Therapy™" technology is patented in Italy and applications for patents have been filed in the U.S. and internationally and are pending approval. The Calmare® device has CE Mark certification from the European Union as well as U.S. FDA 510(k) clearance.

The agreement with Professor Marineo and Delta enabled the Company to establish an agreement with GEOMC Co., Ltd. ("GEOMC", formerly Daeyang E & C Co., Ltd.) of Seoul, South Korea, to manufacture the Calmare® pain therapy medical device, based on Prof. Marineo's "Scrambler Therapy™" technology. The GEOMC agreement is for a

period of ten (10) years and outlines each company's specific financial obligations.

The Company has entered into a number of international distribution agreements, at one time covering nearly 40 countries. The Company conducted a review of its distribution partners during the five-month period ending December 31, 2010, leading to the termination of CTTC's agreement with Life Epistème Group, srl ("LEG"). LEG had the distribution rights in 34 countries, but had not met its minimum obligations to CTTC, and the Company had no indication that LEG would meet its commitments in the foreseeable future.

Following the Company's termination of the LEG distribution agreement, the Company took possession of 55 Calmare® devices which LEG had purchased in fiscal 2010 but had not paid for. The receivable associated with the fiscal 2010 sales was written off as uncollectible and those 55 devices were brought into the Company's inventory at cost. Further review of the Company's receivables found several other small receivables, which were deemed uncollectible and were also cancelled and included as a bad debt expense in the transitional period ended December

31, 2010. In the same period, the Company reversed previously accrued commissions associated with a cancelled consulting contract relating to the sales of these devices.

Following the Company's termination of the LEG distribution agreement, the Company also revoked LEG's distribution rights in all 34 countries previously assigned to LEG. LEG has no further right to sell or distribute Calmare® devices in any location. During the nine months ended September 30, 2011, CTTC contracted a new Managing Director for International Business Development, to take more active control of its international sales. CTTC currently has international distribution agreements covering 21 countries, with other distribution agreements in various stages of negotiation.

During the quarter ended March 31, 2011, CTTC negotiated a new distribution agreement with Life Episteme Italia ("LEI") for the countries of Italy and Malta. As a part of that agreement, LEI purchased 53 of the 55 devices CTTC had taken back into inventory from LEG. Payments for those sales were to be made in accordance with the schedule incorporated into the agreement, with the final payment to be made in the second quarter of CTTC's 2011 fiscal year, but not later than June 30, 2011. All payments from LEI have been received, with the exception of payment for four (4) devices which were found to have been damaged in shipment and are being replaced. Payment for those devices will be completed upon LEI's receipt of the replacement devices, which were shipped to LEI and are being analyzed. In addition to the purchase of the 53 devices previously described, the distribution agreement with LEI contained quarterly and annual marketing and sales requirements which LEI must meet in order to retain continued exclusivity within LEI's territory.

In 2010, the Company became its own distributor in the U.S, contracting with over 20 commissioned sales representatives. During the nine months ended September 30, 2011, the Company conducted a review of its sales representatives. The Company and its representatives have developed plans to increase awareness of the Calmare device among critical medical specialties and will be targeting specific customers and locations in the next fiscal quarter and into fiscal 2012.

Over the past 18 months, the Company entered into several sales agreements for the Calmare® device. Additional U.S. sales agreements were finalized during the nine months ended September 30, 2011, including sales to U.S. government entities within the U.S. Department of Defense and the U.S. Department of Veterans Affairs. Sales to these physicians and medical practices and to others with whom the Company had existing sales agreements are generating revenue for the Company.

Prior to 2011, we earned revenue in three ways, retained royalties from licensing our clients' and our own technologies to our customer licensees, product sales fees in a business model that allows us to share in the profits of distribution of finished products, and sales of inventory. We recorded revenue when the terms of the sales arrangement were accepted by all parties, including a fee that was fixed or determinable, delivery had occurred and our customer had taken title, and collectability was reasonably assured.

Prior to 2011, the Company accounted for revenue from device sales in two ways, depending on the nature of the sale.

§

Sale of inventory shipped directly from the manufacturer in Korea

The Company recorded revenue net because the manufacturer, GEOMC, was responsible for maintaining control of the inventory, shipping the device(s), had inventory credit risk and we earned a fixed amount.

§

Sale of inventory located in the United States

The Company recorded gross revenue, because it was responsible for the inventory and for shipping the device(s).

Beginning in 2011, we earn revenue in two ways: retained royalties from licensing our clients' and our own technologies to our customer licensees, and sales of finished products. We record revenue when the terms of the sales arrangement are accepted by all parties including a fee that is fixed and determinable, delivery has occurred and our customer has taken title, and collectability is reasonably assured.

In 2011 the Company has taken greater control of the sales process, worldwide. We are the primary obligor, responsible for delivering devices as well as for training our customers in the proper use of the device. We deal directly with customers, setting pricing and providing training; work directly with the inventor of the technology to develop specifications and any changes thereto and to select and contract with manufacturing partners; and retain significant credit risk for amounts billed to customers. Therefore, all product sales are now recorded following a gross revenue methodology.

2.

NET INCOME (LOSS) PER COMMON SHARE

The following sets forth the denominator used in the calculations of basic net income (loss) per share and net income (loss) per share assuming dilution:

	Three months ended September 30, 2011	Nine months ended September 30, 2011	Three months ended October 31, 2010	Nine months ended October 31, 2010
Denominator for basic net income (loss) per share, weighted average shares outstanding	14,255,351	13,994,740	13,824,944	12,232,955
Dilutive effect of common stock options	N/A	N/A	N/A	N/A
Dilutive Effect of Series C convertible preferred stock	N/A	N/A	N/A	N/A
Denominator for diluted net income (loss) per share, weighted average shares outstanding	14,255,351	13,994,740	13,824,944	12,232,955

Options to purchase 320,000 and 309,000 shares of our common stock at September 30, 2011 and October 31, 2010, respectively, were outstanding and 375 shares of convertible preferred stock at September 30, 2011 were not included in the computation of diluted net income (loss) per share because they were anti-dilutive.

3.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Fair Value Disclosures. In January 2010, the FASB issued an accounting standards update that requires new disclosures for transfers in and out of Levels 1 and 2 fair value measurements, and roll forward of activity in Level 3 fair value measurements. The new disclosures are effective for reporting periods beginning after December 15, 2009, except for the roll forward of activity in Level 3 fair value measurements. Those disclosures are effective for fiscal years beginning after December 15, 2010. Upon adoption, this standard did not have a material impact on the financial statements.

No other new accounting pronouncements issued or effective during the three and nine months ended September 30, 2011 has had or is expected to have a material impact on the consolidated financial statements.

4.

RECEIVABLES

Receivables consist of the following:

	September 30,	December 31,
	2011	2010
Calmare® Sales Receivable	\$	\$
	350,458	-
Other Receivable	10,732	7,048
Royalties, net of allowance of \$101,154		
at September 30, 2011 and December 31, 2010	-	17,954
Total receivables	\$	\$
	361,190	25,002

5.

AVAILABLE-FOR-SALE AND EQUITY SECURITIES

The fair value of the equity securities we held were categorized as available-for-sale securities, which were carried at a fair value of zero, consisted of shares in Security Innovation and Xion Pharmaceutical. We own 223,317 shares of stock in the privately held Security Innovation, an independent provider of secure software located in Wilmington, MA.

In September 2009 we announced the formation of a joint venture with Xion Corporation for the commercialization of our patented melanocortin analogues for treating sexual dysfunction and obesity. CTTC currently owns 60 shares of common stock or 33% of the outstanding stock of privately held Xion Pharmaceutical Corporation.

6.

FAIR VALUE MEASUREMENTS

The Company measures fair value in accordance with Topic 820 of the FASB Accounting Standards Codification ("ASC"), "Fair Value Measurements and Disclosures" ("ASC 820"), which provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described as follows:

Level 1 -

Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.

Level 2 -

Inputs to the valuation methodology include:

-

Quoted prices for similar assets or liabilities in active markets;

-

Quoted prices for identical or similar assets or liabilities in inactive markets;

-

Inputs other than quoted prices that are observable for the asset or liability;

-

Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 -

Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The Company values its derivative liability associated with the variable conversion feature on its Series C Convertible Preferred Stock (Note 11) based on the market price of its common stock. For each reporting period the Company calculates the amount of potential common stock that the Series C Preferred Stock could convert into based on the conversion formula (incorporating market value of our common stock) and multiplies those converted shares by the market price of its common stock on that reporting date. The total converted value is subtracted by the consideration paid to determine the fair value of the derivative liability.

The method described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value could result in a different fair value measurement at the reporting date.

The Company classified the derivative liability of \$67,781 and \$132,353 at September 30, 2011 and December 31, 2010, respectively, in Level 2 of the fair value hierarchy.

The carrying amounts reported in our Condensed Consolidated Balance Sheet for Cash and Cash Equivalents, Accounts Receivable, Due From Factor, Accounts Payable, Notes Payable, Accrued Expenses and Other Liabilities and Preferred Stock Liability approximate fair value due to the short-term maturity of those financial instruments.

7.

PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following:

	<u>September 30, 2011</u>	<u>December 31, 2010</u>
Prepaid insurance	\$ 18,638	\$ 30,081
Prepaid investor relations service	-	20,000
Travel advances	30,000	-
Other	<u>23,945</u>	<u>27,871</u>
Prepaid expenses and other current assets	<u>\$ 72,583</u>	<u>\$ 77,952</u>

8.

PROPERTY AND EQUIPMENT

Property and equipment, net, consist of the following:

	September 30, 2011	December 31, 2010
Property and equipment, gross	227,646	225,057
Accumulated depreciation and amortization	(198,791)	(184,415)
Property and equipment, net	\$	\$
	28,855	40,642

Depreciation and amortization expense was \$3,910 during the three months ended September 30, 2011, and \$14,473 during the three months ended October 31, 2010. Depreciation and amortization expense was \$17,400 during the nine months ended September 30, 2011, and \$40,826 during the nine months ended October 31, 2010.

9.

ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consist of the following:

	September 30, 2011	December 31, 2010
	\$	\$
Royalties payable	339,712	41,394
Deferred compensation	13,438	93,167
Accrued legal fees		66,251
Accrued accounting fees	84,279	54,170
Deferred Revenue	87,800	-
Other accrued liabilities	160,723	152,141
	\$	\$
Accrued Expenses and Other Liabilities	685,952	407,123

Deferred revenue includes 16 training days which were purchased but not conducted during the quarter ended September 30, 2011. Deferred revenue also includes sale of five (5) Calmare devices to an international distributor initiated but not completed during the quarter ended September 30, 2011. Fifty percent (50%) of the funds for the sale were received in the quarter ended September 30, 2011, but the devices have not yet been shipped per the customer's request.

10.

NOTES PAYABLE

In March 2011, the Company issued a 90-day note payable to borrow \$50,000. The proceeds were used for general corporate purposes. The full amount of principal and 5.00% simple interest per annum was paid during the quarter ended June 30, 2011. In the quarter ended September 30, 2011, two notes payable were issued to borrow \$50,000 and \$100,000. The proceeds were used for general corporate purposes. At September 30, 2011, the full amount of the principal and 6.00% simple interest per annum were still outstanding; however as of November 14, 2011, the date of this report, both notes and interest owed have been paid in full.

11.

SHAREHOLDERS INTEREST

On August 18, 2011 the Company filed a Form S-8 Registration Statement to register 109,219 common shares, issuable in lieu of directors' fees and for legal services. During August 2011, the company issued 100,000 common shares to attorneys to settle \$125,000 accrued liabilities. Also during August 2011, the company issued 9,219 common shares to two of its directors in lieu of \$13,000 of accrued directors' fees.

On May 2, 2011 the Company adopted and executed the Employees', Directors' and Consultants Stock Option Plan (the Plan). In addition on May 2, 2011 we granted each Director 10,000 options (40,000 in total) as prescribed by the plan.

We estimated the fair value of each option on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions:

Nine Months Ended September 30, 2011

Dividend yield (1)

0.0%

Expected volatility (2)

89.95%

Risk-free interest rates (3)

1.96%

Expected lives (2)

5 YEARS

(1)

We have not paid cash dividends on our common stock since 1981, and currently do not have plans to pay or declare cash dividends. Consequently, we used an expected dividend rate of zero for the valuations.

(2)

Estimated based on our historical experience. Volatility was based on historical experience over a period equivalent to the expected life in years.

(3)

Based on the U.S. Treasury constant maturity interest rate with a term consistent with the expected life of the options granted.

During the three months and nine months ended September 30, 2011, the Company recognized expense of \$6,866 and \$67,639, respectively, for stock options issued to employees and directors. During the three and nine months ended October 31, 2010, the Company recognized expense of \$8,972 and \$17,887, respectively, for stock options issued to employees and directors.

On June 2, 2010, we entered into an agreement with Crisnic Fund, S.A. ("Crisnic") to sell up to two million shares of our common stock to Crisnic at a 15% discount from the volume weighted average price on the date the SEC declared our registration statement effective.

Following the closing date for the sale, the stock price went down rapidly, to the point where Crisnic was unable to complete the funding for the transaction. Because the stock was trading below the discounted price of \$2.04, portions of the shares could not be sold to third parties at the agreed-upon price, as had been planned by Crisnic. Shares were sold in several tranches, initially at the agreed upon price per share of \$2.04, and as market conditions worsened, at lower prices which would still enable the Company to receive the necessary financing. No shares were sold below \$0.90.

The Company ultimately received approximately \$1.6 million for the sale of 1,447,867 shares of common stock (including 75,000 shares given to Crisnic as a fee). These shares were sold between July 14, 2010, which was the date the registration statement was declared effective by the Securities and Exchange Commission, and September 15, 2010. The remaining 627,133 shares of stock were outstanding and were reflected as a receivable reducing equity in our financial statements for the quarter ended October 31, 2010. These shares were valued at \$0.90. Plans to sell these shares had been halted due to market conditions. In November 2010, the Company and Crisnic agreed to cancel 602,133 common shares previously issued on subscription and canceled the related \$541,920 receivable. During January 2011 the Company and Crisnic canceled 15,000 additional shares previously issued on subscription and canceled the related \$13,500 receivable. During February 2011 the Company and Crisnic canceled 10,000 additional shares previously issued on subscription and canceled the related \$9,000 receivable.

The 627,133 shares were reissued. In November 2010, the Company issued 69,528 shares to attorneys and the contractor where the CEO is employed to settle \$85,900 of accounts payable. In December 2010, an additional 532,605 shares were sold for approximately \$505,000. In January 2011 the Company issued 15,000 shares to attorneys to settle \$16,350 of accrued liabilities. In February 2011 the Company issued 10,000 shares to the Company Executive Vice President to settle \$9,900 of deferred payroll.

At its December 2, 2010 meeting, the CTTC Board of Directors declared a dividend distribution of one right (each, a Right) for each outstanding share of common stock, par value \$0.01, of the Company (the Common Shares). The dividend is payable to holders of record as of the close of business on December 2, 2010 (the Record Date). Issuance of the dividend may be triggered by an investor purchasing more than 20% of the outstanding shares of common stock. This shareholder rights plan and the subsequent authorization of 20,000 shares of Class B Preferred Stock were announced with a Form 8-K filing on December 15, 2010, following CTTC's finalization of the Rights Agreement with CTTC's Rights Agent, American Stock Transfer & Trust Company, LLC. The Rights Agreement was filed with the December 15, 2010, Form 8-K. It is intended to provide the CTTC Board of Directors with time for proper valuation of the Company should other entities attempt to purchase a controlling interest of CTTC shares.

On December 15, 2010 the Company issued a \$400,000 promissory note. The promissory note was scheduled to mature on December 31, 2012 with an annual interest rate of 5%.

On December 15, 2010, the Company's Board of Directors authorized the issuance of 750 shares of Series C Convertible Preferred Stock (\$1,000 par value) with a 5% cumulative dividend to William R. Waters, Ltd. of Canada. On December 30, 2010, 750 shares were issued. The Company converted a \$400,000 promissory note into 400 shares and received cash of \$350,000 for the remaining 350 shares. These transactions were necessitated to replenish the Company's operating cash which had been drawn down by the \$750,000 cash collateral previously posted by CTTC in a

prejudgment remedy action styled *John B. Nano v. Competitive Technologies, Inc.*, Docket No. CV10 5029318 (Superior Court, Bridgeport, CT), see Note 12 below for details.

On June 17, 2011, William R. Waters, Ltd. of Canada, advised the Company of its intent to convert one half of its Series C Convertible Preferred Stock, 375 shares, to common stock, with a conversion date of June 16, 2011. On July 14, 2011, American Stock Transfer & Trust Company was asked to issue the certificate for 315,126 shares of CTTC common stock. In accordance with the conversion rights detailed below, the conversion price for these shares was \$1.19, which is 85% of the mid-point of the last bid price (\$1.35) and the last ask price (\$1.45) on June 16, 2011, the agreed upon conversion date.

The rights of the Series C Convertible Preferred Stock are as follows:

Dividend rights The shares of Series C Convertible Preferred Stock accrue a 5% cumulative dividend on a quarterly basis and is payable on the last day of each fiscal quarter when declared by the Company's Board. As of September 30, 2011 dividends declared were \$23,473 of which \$4,726 have not been paid and are shown in accrued and other liabilities at September 30, 2011.

Voting rights Holders of these shares of Series C Convertible Preferred Stock shall have voting rights equivalent to 1,000 votes per \$1,000 par value Series C Convertible Preferred share voted together with the shares of common stock

Liquidation rights Upon any liquidation these Series C Convertible Preferred Stock shares shall be treated as equivalent to shares of Common stock to which they are convertible.

Redemption rights

-

Holder may demand redemption of outstanding Series C Convertible Preferred Stock shares by the Company at a price equal to par plus any accrued but unpaid dividends in the event that the \$750,000 escrow by the Company has been released and returned to the company.

-

The Company may upon notice to holder redeem all or any portion of outstanding Series C Convertible Preferred Stock shares by the Company at a price equal to par plus any accrued but unpaid dividends in the event that the \$750,000 escrow by the Company has been released and returned to the company. However, the holder may elect to convert (see conversion rights below) the preferred shares upon receipt of such notice.

Conversion rights Holder has right to convert each share of Series C Convertible Preferred Stock at any time into shares of the Company's common stock at a conversion price for each share of common stock equal to 85% of the lower of (1) the closing market price at the date of notice of conversion or (2) the mid-point of the last bid price and the last ask price on the date of the notice of conversion. The variable conversion feature creates an embedded derivative that was bifurcated from the Series C Convertible Preferred Stock on the date of issuance and was recorded at fair value. The derivative liability will be recorded at fair value on each reporting date with any change recorded in the Statement of Operations as an unrealized gain (loss) on derivative instrument.

On the date of conversion of the 375 shares of Series C Convertible Preferred Stock the Company calculated the value of the derivative liability to be \$81,933 and recorded an unrealized loss of \$15,678 and \$14,281 for the six and three months ended June 30, 2011 related to the converted shares. Upon conversion, the \$81,933 derivative liability was reclassified to equity.

The Company recorded a convertible preferred stock derivative liability of \$67,781, associated with the 375 shares of Series C Convertible Preferred Stock outstanding at September 30, 2011, and \$132,353, associated with the original 750 shares of Series C Convertible Preferred Stock outstanding at December 31, 2010.

The Company has classified the Series C Convertible Preferred Stock as a liability at September 30, 2011 and December 31, 2010 because the variable conversion feature may require the Company to settle the conversion in a variable number of its common shares.

12.

CONTRACTURAL OBLIGATIONS AND CONTINGENCIES

As of September 30, 2011, CTTC and its majority-owned subsidiary, VVI, have remaining obligations, contingent upon receipt of certain revenue, to repay up to \$168,858 and \$202,124, respectively, in consideration of grant funding received in 1994 and 1995. CTTC is also obligated to pay at the rate of 7.5% of its revenue, if any, from transferring rights to certain inventions supported by the grant funds. VVI is obligated to pay at rates of 1.5% of its net sales of supported products or 15% of its revenue from licensing supported products, if any. We recognize these obligations when we receive revenue related to the grant funds. We recognized \$180 of these obligations during the quarter ended September 30, 2011.

On November 22, 2010, the Company terminated its operating lease and paid the landlord all existing obligations thereto. The Company then entered into a new, three-year operating lease for new, more appropriately sized office spaces. The obligations are significantly less than the previous lease, averaging \$70,000 per year for the three-year term. Under the previous lease, rent and utility obligations would have been approximately \$300,000 per year for that same period.

In January 2011, the Company entered into a two-year lease effective February 1, 2011 for additional office space for the sales and training staff in Charlotte, NC. Obligations under this lease average \$27,000 per year for the two-year term.

Carolina Liquid Chemistries Corporation, et al. (Case pending) On August 29, 2005, we filed a complaint against Carolina Liquid Chemistries Corporation ("Carolina Liquid") in the United States District Court for the District of Colorado, alleging patent infringement of our patent covering homocysteine assays, and seeking monetary damages, punitive damages, attorneys' fees, court costs and other remuneration at the option of the court. As we became aware of other infringers, we amended our complaint to add as defendants Catch, Inc. ("Catch") and the Diazyme Laboratories Division of General Atomics ("Diazyme"). On September 6, 2006, Diazyme filed for declaratory judgment in the Southern District of California for a change in venue and a declaration of non-infringement and invalidity. On September 12, 2006, the District Court in Colorado ruled that both Catch and Diazyme be added as defendants to the Carolina Liquid case.

On October 23, 2006, Diazyme requested the United States Patent and Trademark Office (the "USPTO") to re-evaluate the validity of our patent and this request was granted by the USPTO on December 14, 2006. On July 30, 2009, the U.S. Patent and Trademark Office's Board of Patent Appeals and Interferences (BPAI) upheld the

homocysteine patent. In September 2008, the examiner had denied the patent, but that denial was overruled by the BPAI. While the examiner had appealed that BPAI decision, delaying further action, that appeal was also denied by the BPAI on December 13, 2010. In June 2011, the examiner once again appealed the BPAI decision, and the status of that appeal pends further action by the USPTO. In addition to responding to this new appeal, the Company has petitioned the Director of the USPTO to help expedite further action on the case within the USPTO, which was to have been handled with special dispatch according to USPTO requirements for handling reexamination proceedings of patents involved in litigation. Future action on this case pends final documentation of the BPAI denial from the USPTO, prior to being returned to the U.S. District Court for the District of Colorado.

Employment matters former employee (Case completed) In September 2003, a former employee filed a whistleblower complaint with OSHA alleging that the employee had been terminated for engaging in conduct protected under the Sarbanes Oxley Act of 2002 (SOX). In February 2005, OSHA found probable cause to support the employee's complaint and the Secretary of Labor ordered reinstatement and back wages since the date of termination and CTCC requested de novo review and a hearing before an administrative law judge (ALJ). In July 2005, after the close of the hearing on CTCC's appeal, the U.S. district court for Connecticut enforced the Secretary's preliminary order of reinstatement and back pay under threat of contempt and the company rehired the employee with back pay.

On October 5, 2005, the ALJ who conducted the hearing on CTTC's appeal of the OSHA findings ruled in CTTC's favor and recommended dismissal of the employee's complaint. Although the employee abandoned his position upon notice of the ALJ's decision, he nevertheless filed a request for review by the DOL Administrative Review Board ("ARB").

In May 2006, the U.S. Court of Appeals for the Second Circuit vacated the order of the district court enforcing the Secretary's preliminary order of reinstatement and back pay. The employee also filed a new SOX retaliation complaint with OSHA based on alleged black listing action by CTTC following his termination. OSHA dismissed the complaint and the employee filed a request for a hearing by an administrative law judge. Ultimately, the employee voluntarily dismissed the appeal.

In March 2008, the ARB issued an order of remand in the employee's appeal of the October 2005 dismissal of his termination complaint, directing the ALJ to clarify her analysis utilizing the burden-shifting standard articulated by the ARB. In January 2009, the ALJ issued a revised decision again recommending dismissal and once again the employee appealed the ruling to the ARB. On September 30, 2011, the ARB issued a final decision and order affirming the ALJ's decision on remand and dismissing the employee's complaint.

John B. Nano vs. Competitive Technologies, Inc. (Arbitration) On September 3, 2010, the Board of Directors of CTTC removed John B. Nano as an Officer of the Corporation, in all capacities, for cause, consisting of violation of his fiduciary duties to the Corporation and violation of the CTTC Corporate Code of Conduct. On September 13, 2010, the Board of Directors also removed John B. Nano as a Director of the Corporation, in all capacities, for cause, consisting of violation of his fiduciary duties to the Corporation and violation of the CTTC Corporate Code of Conduct. Details of these actions are outlined in Form 8-K filings with the SEC on September 13, 2010, and September 17, 2010. Mr. Nano was previously the Chairman of the Board of Directors, President and Chief Executive Officer of CTTC.

On September 13, 2010, Mr. Nano brought an arbitration claim to the American Arbitration Association against CTTC. Mr. Nano's employment contract with the Company had called for arbitration, which Mr. Nano has been requested to resolve this conflict. Mr. Nano is seeking \$750,000 that he claimed is owed under his contract had he been terminated without cause.

On September 23, 2010 the Company was served notice that John B. Nano, CTTC's former Chairman, President and CEO had filed a Notice of Application for Prejudgment Remedy/Claim of \$750,000 and an Application for an Order Pendente Lite for breach of his employment contract with us. The applications were filed in the State of Connecticut Superior Court in Bridgeport, CT. In November 2010, the Company funded \$750,000 as a Prejudgment Remedy held in escrow with the Company's counsel and has included this amount as restricted cash on the September 30, 2011 and December 31, 2010 balance sheets. The Company does not believe it is liable to the former Chairman, President and CEO as he was terminated for cause. The case proceeded through the arbitration process. The initial arbitration hearing began in April 2011; additional hearing dates were held in May and June 2011. In July 2011, each party submitted a summary limited in length of their position.

Prior to the conclusion of the arbitration hearings, the Company filed suit in Federal Court against the American Arbitration Association. The Company requested a temporary restraining order to halt the arbitration, which was denied by the court. The Company also requested a hearing before the judge to review the arbitration proceedings. The Company's request for a hearing is pending.

In August 2011, the American Arbitration Association's assigned arbitrator gave award to the Company's former Chairman, President and CEO, despite the Company's strongly held belief that the Board of Directors exercised its reasonable discretion in finding that the former executive engaged in willful misconduct and gross negligence and that the executive's actions were cause for employment termination under the employment agreement and governing law. The former executive had requested a payment of \$750,000, which he believed was due under his employment agreement. Following the notification of award, the former employee filed a motion with the State of Connecticut Superior Court in Bridgeport, CT to have the award confirmed. CTTC followed with a motion to vacate

the award. A hearing on the two motions was held before a judge in October 2011. The judge is reviewing all documents submitted by both parties and is expected to render a decision, in late November 2011.

Unfair Trade Practices (U.S. District Court of Connecticut) In September 2011, the Company filed a complaint against an individual in U.S. District Court of Connecticut for (1) violation of the Connecticut Unfair Trade Practices Act, (2) tortious interference with business and economic expectancy, (3) libel and (4) injunctive relief. The complaint noted that the individual named in the civil action has, for more than a year, engaged in a systematic campaign to destroy the Company's trades and business, interfere with the Company's expectations and contracts and libel the Company by disseminating materially false and libelous statements about the Company on message boards throughout the Internet and otherwise. The Company is seeking punitive damages from the individual for his alleged unfair trade practices and wrongful interference with the Company's business. The case is in its early stages and is not expected to conclude prior the end of the 2011 fiscal year.

Summary We may be a party to other legal actions and proceedings from time to time. We are unable to estimate legal expenses or losses we may incur, if any, or possible damages we may recover, and have not recorded any potential judgment losses or proceeds in our financial statements to date. We record expenses in connection with these suits as incurred.

We believe we carry adequate liability insurance, directors and officers insurance, casualty insurance, for owned or leased tangible assets, and other insurance as needed to cover us against potential and actual claims and lawsuits that occur in the ordinary course of our business. However, an unfavorable resolution of any or all matters, and/or our incurrence of significant legal fees and other costs to defend or prosecute any of these actions and proceedings may, depending on the amount and timing, have a material adverse effect on our consolidated financial position, results of operations or cash flows in a particular period.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Statements about our future expectations are forward-looking statements within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used in herein, the words "may," "will," "should," "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in Item 1A under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2010, filed with the Securities and Exchange Commission ("SEC") on October 27, 2010, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Overview

Competitive Technologies, Inc. ("CTTC") was incorporated in Delaware in 1971, succeeding an Illinois corporation incorporated in 1968. CTTC and its majority owned subsidiary (collectively, "we", "our", or "us") provide distribution, patent and technology transfer, sales and licensing services focusing on the needs of our customers, matching those requirements with commercially viable technology or product solutions. We develop relationships with universities, companies, inventors and patent or intellectual property holders to obtain the rights or a license to their intellectual property or to their product. They become our clients, for whom we find markets to sell or further develop or distribute their technology or product. We also develop relationships with those who have a need or use for technologies or products. They become our customers, usually through a license or sublicense, or distribution agreement.

Our revenue fluctuates due to changes in revenue of our customers, upfront license fees, new licenses granted, new distribution agreements, expiration of existing licenses or agreements, and/or the expiration or economic obsolescence of patents underlying licenses or products.

We acquire rights to commercialize a technology or product on an exclusive or non-exclusive basis, worldwide or limited to a specific geographic area. When we license or sublicense those rights to our customers, we may limit rights to a defined field of use. Technologies can be early, mid, or late stage. Products we evaluate must be working prototypes or finished products. We establish channel partners based on forging relationships with mutually aligned goals and matched competencies to deliver solutions that benefit the ultimate end-user.

We earn revenue from retained royalties from licensing our clients' and our own technologies to our customer licensees and sales of finished products. Our customers pay us license fees, royalties based on usage of a technology, or per unit fees, and we share that revenue with our clients.

Prior to 2011, we earned revenue in three ways, retained royalties from licensing our clients' and our own technologies to our customer licensees, product sales fees in a business model that allows us to share in the profits of distribution of finished products, and sales of inventory. We recorded revenue when the terms of the sales arrangement were accepted by all parties, including a fee that was fixed or determinable, delivery had occurred and our customer had taken title, and collectability was reasonably assured.

Prior to 2011, the Company accounted for revenue from device sales in two ways, depending on the nature of the sale.

§

Sale of inventory shipped directly from the manufacturer in Korea

The Company recorded revenue net because the manufacturer, GEOMC, was responsible for maintaining control of the inventory, shipping the device(s), had inventory credit risk and we earned a fixed amount.

§

Sale of inventory located in the United States

The Company recorded gross revenue, because it was responsible for the inventory and for shipping the device(s).

Beginning in 2011, we earn revenue in two ways, retained royalties from licensing our clients' and our own technologies to our customer licensees and sales of finished products. We record revenue when the terms of the sales arrangement are accepted by all parties, delivery has occurred and our customer has taken title, and collectability is reasonably assured.

In 2011 the Company has taken greater control of the sales process, worldwide. We are the primary obligor, responsible for delivering devices as well as training our customer in the proper use of the device. We deal directly with customers, setting pricing and providing training; work directly with the inventor of the technology to develop specifications and any changes thereto and to select and contract with manufacturing partners; and retain significant credit risk for amounts billed to customers. Therefore, all product sales are now recorded following a gross revenue methodology. We record in Product sales, the total funds invoiced and received from customers and record the costs of the device as Cost of product sales, with Gross profit from product sales being the result.

Sales of our Calmare[®] pain therapy medical device continue to be the major source of revenue for the Company. The Company acquired the exclusive, worldwide rights to the "Scrambler Therapy" technology in 2007. The Company's agreement with Giuseppe Marineo, the inventor of "Scrambler Therapy" technology, and Delta Research and Development ("Delta"), authorizes CTTC to manufacture and sell worldwide the device developed from the patented "Scrambler Therapy" technology. The "Scrambler Therapy[™]" technology is patented in Italy and applications for patents have been filed in the U.S. and internationally and are pending approval. The Calmare[®] device has CE Mark certification from the European Union as well as U.S. FDA 510(k) clearance.

The agreement with Professor Marineo and Delta enabled the Company to establish an agreement with GEOMC Co., Ltd. ("GEOMC", formerly Daeyang E & C Co., Ltd.) of Seoul, South Korea, to manufacture the Calmare[®] pain therapy medical device, based on Prof. Marineo's "Scrambler Therapy[™]" technology. The GEOMC agreement is for a period of ten (10) years and outlines each company's specific financial obligations.

The Company has entered into a number of international distribution agreements, at one time covering nearly 40 countries. The Company conducted a review of its distribution partners during the five-month period ending December 31, 2010, leading to the termination of CTTC's agreement with Life Epist me Group, srl ("LEG"). LEG had the distribution rights in 34 countries, but had not met its minimum obligations to CTTC, and the Company had no indication that LEG would meet its commitments in the foreseeable future.

Following the Company's termination of the LEG distribution agreement, the Company took possession of 55 Calmare[®] devices (device) which LEG had purchased in fiscal 2010 but had not paid for. The receivable associated with the fiscal 2010 sales was written off as uncollectable and those 55 devices were brought into the Company's inventory at cost. Further review of the Company's receivables found several other small receivables which were deemed uncollectable and were also cancelled and included as a bad debt expense in the transitional period ended December 31, 2010. Lastly, the Company reversed previously accrued commissions associated with a cancelled consulting contract relating to the sales of these devices.

Following the Company's termination of the LEG distribution agreement, the Company also revoked LEG's distribution rights in all 34 countries previously assigned to LEG. LEG has no further right to sell or distribute Calmare® devices in any location. During the quarter ended March 31, 2011, CTTC contracted a new Managing Director for International Business Development, to take more active control of its international sales. CTTC has international distribution agreements covering 21 countries, with additional distribution agreements in various stages of negotiation, which are expected to generate revenue for the Company in the fourth quarter of fiscal 2011 and into the next two fiscal years.

During the quarter ended March 31, 2011, CTTC negotiated a new distribution agreement with Life Episteme Italia ("LEI") for the countries of Italy and Malta. As a part of that agreement, LEI purchased 53 of the 55 devices CTTC had taken back into inventory from LEG. Payments for those sales were to be made in accordance with the schedule incorporated into the agreement, with the final payment to be made in the second quarter of CTTC's 2011 fiscal year, but not later than June 30, 2011. All payments from LEI have been received, with the exception of

payment for four (4) devices which were found to have been damaged in shipment and are being replaced. Payment for those devices will be completed upon LEI's receipt of the replacement devices, which were shipped to LEI and are being analyzed. In addition to the purchase of the 53 devices previously described, the distribution agreement with LEI contained quarterly and annual marketing and sales requirements which LEI must meet in order to retain continued exclusivity within LEI's territory.

In 2010, the Company became its own distributor in the U.S, contracting with over 20 commissioned sales representatives. During the nine months ended September 30, 2011, the Company conducted a review of its sales representatives. The Company and its representatives have developed plans to increase awareness of the Calmare device among critical medical specialties and will be targeting specific customers and locations in the next fiscal quarter and into fiscal 2012.

Over the past 18 months, the Company entered into several sales agreements for the Calmare[®] device. Additional U.S. sales agreements were finalized during the nine months ended September 30, 2011, including sales to U.S. government entities within the U.S. Department of Defense and the U.S. Department of Veterans Affairs. Sales to these physicians and medical practices and to others with whom the Company had existing sales agreements are generating revenue for the Company.

On November 15, 2010, the Board of Directors of CTTC approved a fiscal year-end change from July 31 to December 31, in order to align its fiscal periods with the calendar year. The Company filed a Transitional Report on Form 10-Q for the two and five months ended December 31, 2010. CTTC will subsequently file its quarterly and annual reports for fiscal years ending December 31. CTTC's annual report on Form 10-K for the fiscal year ending December 31, 2011 will include separate audited financial statements for the five-month transitional period.

Presentation

We rounded all amounts in this Item 2 to the nearest thousand dollars. Certain amounts may not total precisely.

The following discussion and analysis provides information that we believe is relevant to an assessment and understanding of our financial condition and results of operations. This discussion and analysis should be read in conjunction with our Consolidated Financial Statements and Notes thereto.

Results of Operations Three months ended September 30, 2011 vs. three months ended October 31, 2010

Summary of Results

We incurred a net loss of \$538,000 or \$0.04 per basic and diluted share for the three months ended September 30, 2011, compared to a net loss of \$1,094,000 or \$0.08 per basic and diluted share for the three months ended October 31, 2010. As explained in detail below, the net loss reflects an increase of \$1,090,000 in gross revenue, an increase of \$603,000 in gross profit from product sales and an increase in other expenses of \$49,000.

Revenue and Gross Profit from Sales

Revenue from product sales: In the three months ended September 30, 2011, we recorded \$1,198,000 in revenue from the sale and shipment of 22 (2 internationally, 20 domestic) Calmare[®] pain therapy medical devices; with a cost of product sales of \$505,000. In the three months ended October 31, 2010, we recorded \$108,000 in gross revenue from the sale and shipment of two (2 domestic) Calmare[®] pain therapy medical devices, with a cost of product sales of \$18,000.

Other Revenue

Retained royalties for the three months ended September 30, 2011, were \$4,000, which was \$3,000, or 43% less than the \$7,000 of retained royalties reported in the three months ended October 31, 2010.

Other income for the three months ended September 30, 2011, was \$9,000, including payments for training and the sale of supplies such as electrodes and cables for use with our Calmare[®] devices (\$4,000) and rental income (\$5,000) from customers who were renting Calmare[®] pain therapy medical devices from us. Approximately \$4,000 of other income consisting of rental income from customers who were renting Calmare[®] pain therapy medical devices from us was reported in the three months ended October 31, 2010.

Expenses

Total expenses were \$1,245,000 in the three months ended September 30, 2011 compared to \$1,196,000 in the three months ended October 31, 2010, an increase of \$49,000 or 4%.

Selling expenses were \$219,000 in the three months ended September 30, 2011, compared to \$56,000 in the three months ended October 31, 2010. The increase of \$163,000 was primarily due to an increase of \$26,000 in domestic patent legal expenses related to the joint venture with XION Corporation to develop the melanocortin technologies, an increase of \$106,000 in commission expenses related to increased sales of Calmare[®] devices, and an increase of \$30,000 in patent and translation fees related to working with the inventor of the Calmare[®] device.

Personnel and consulting expenses were \$431,000 in the three months ended September 30, 2011, as compared to \$504,000 in the three months ended October 31, 2010, a reduction of \$73,000 or 14%. Personnel and related benefit expenses were lower (\$137,000) in the quarter ended September 30, 2011, due to the reduction of the staff size from ten (10) in October 2010 to seven (7) at the end of September 30, 2011, and the associated reduction in salaries and benefits, as well as a reduction in the employee stock retirement compensation expense (\$13,000) and a reduction in the employee stock option expense (\$2,000).

Consulting fees for the Medical Advisory Board ("MAB") were lower (\$15,000) in the quarter ended September 30, 2011 than in the prior period, since the MAB did not meet during the quarter. These decreases were offset slightly by an increase (\$7,000) in employee incentive payments. In addition, there were increased consulting fees (\$87,000), primarily due to work related to U.S. and Federal government sales of our Calmare[®] device, the management services of our current CEO, and the work of the contracted Managing Director for International Business Development.

General and administrative expenses were \$601,000 in the three months ended September 30, 2011, a decrease of \$32,000, or 5% from \$633,000 in the three months ended October 31, 2010. The change is primarily due to increases in legal fees (\$70,000) associated with the legal activity relating to the former CEO challenging his termination for cause, increases in legal fees associated with other litigation (\$10,000); increases in subscriptions and dues, supplies and postage and delivery fees due to the increased volume in those activities over the prior year quarter (\$34,000); increases in banking, audit and tax fees (\$5,000), increased insurance expenses (\$3,000); and financing costs associated with the factoring agreement which were not incurred in the prior year quarter (\$3,000). The increases were offset by decreases in investor and public relations expenses due to fewer global press releases being issued and the fact that the Company terminated contracts with several investor relations groups in the prior year quarter so those expenses are no longer being incurred (\$51,000); decreases in rent and associated expenses (\$45,000); a decrease in marketing expenses related to the payment of consultants for marketing our Calmare device in the quarter ended October 31, 2010 which did not recur in the quarter ended September 30, 2011 (\$18,000); a reduction in corporate legal expenses (\$28,000), decreases in directors' fees and expenses (\$2,000); a reduction in travel expenses (\$2,000) due to fewer employees traveling; and a reduced depreciation expense of (\$11,000) due to having less property and equipment to depreciate.

Interest expense increased to \$9,000 in the three months ended September 30, 2011, compared to \$2,000 in the three months ended October 31, 2010, an increase of \$7,000 due primarily to the issuance of Notes payable and Class C Convertible Preferred Stock, during the current year, neither of which were present in the prior year period.

Results of Operations Nine months ended September 30, 2011 vs. Nine months ended October 31, 2010

Summary of Results

We incurred a net loss of \$1,843,000 or \$0.13 per basic and diluted share for the nine months ended September 30, 2011, compared to a net loss of \$2,302,000 or \$0.19 per basic and diluted share for the nine months ended October 31, 2010. As explained in detail below, the net loss reflects an increase of \$1,663,000 in gross revenue, an increase of \$704,000 in gross profit from product sales and an increase in other expenses of \$287,000.

Revenue and Gross Profit from Sales

Revenue from product sales: In the nine months ended September 30, 2011, we recorded \$3,337,000 in revenue from the sale and shipment of 100 (67 internationally, 33 domestic) Calmare[®] pain therapy medical devices; with a cost of product sales of \$1,484,000. In the nine months ended October 31, 2010, we recorded \$1,674,000 in gross revenue from the sale and shipment of 109 (101 internationally, 8 domestic) Calmare[®] pain therapy medical devices, with a cost of product sales of \$525,000. Of the 109 devices sold in the nine months ended October 31, 2010, 100 were sold to the now-defunct distributor, Life Episteme Group ("LEG"). Of those 100 devices, CTTC never received payment from LEG for 55 and ended up bringing the 55 devices back into inventory and writing off the associated receivable as a bad debt during the transition period ended December 31, 2010.

Other Revenue

Gain on sale of rental asset in the nine months ended September 30, 2011; we sold one former rental asset, recording a gain of \$35,000. No such sale occurred in the nine months ended October 31, 2010.

Retained royalties for the nine months ended September 30, 2011, were \$20,000, which was \$18,000, or 47% less than the \$38,000 in retained royalties reported in the nine months ended October 31, 2010.

Other income for the nine months ended September 30, 2011, was \$31,000, including rental income from customers who were renting Calmare® pain therapy medical devices from us (\$16,000) and income from the purchases of training and supplies such as electrodes and cables for use with our Calmare® devices (\$15,000). This was \$26,000 more than the approximately \$5,000 other income, primarily rental income received from customers who were renting Calmare® devices from us during the nine months ended October 31, 2010.

Expenses

Total expenses were \$3,781,000 in the nine months ended September 30, 2011 compared to \$3,494,000 in the nine months ended October 31, 2010, an increase of \$287,000 or 8%.

Selling expenses were \$416,000 in the nine months ended September 30, 2011, compared to \$287,000 in the nine months ended October 31, 2010. The increase of \$129,000 was primarily due to an overall increase of \$101,000 in commission expenses related to sales of Calmare® devices, an increase of \$43,000 in domestic patent legal expenses related to the joint venture with XION Corporation to develop the melanocortin technologies, an increase of \$11,000 in foreign patent legal expenses related to the "Scrambler Therapy" technology, a liability associated with the sale of video compression patents of \$33,000, and an additional \$6,000 in expenses associated with other technologies.

These increases in selling expenses were off set by a \$35,000 reduction in translation, legal and other services directly related to "Scrambler Therapy" and the Calmare® devices, and \$30,000 foreign patent expense incurred in the nine months ended October 31, 2010, which did not recur in the nine months ended September 30, 2011.

Personnel and consulting expenses were \$1,204,000 in the nine months ended September 30, 2011, as compared to \$1,498,000 in the nine months ended October 31, 2010, a decrease of \$294,000, or 20%. Personnel and related benefit expenses were lower in the nine months ended September 30, 2011, due to the reduction in the number of employees from 10 to 7 and the associated reduction in salaries and benefits (\$478,000), as well as a reduction in the employee stock option compensation expense (\$1,000). In the nine months ended October 31, 2010 we incurred recruiting expenses (\$60,000) related to the hiring of a US sales manager and sales representatives, and consulting fees for the Medical Advisory Board (\$35,000) neither of which recurred in the nine months ended September 30, 2011. These decreases were offset by an increase (\$15,000) in employee incentive payments, and increased consulting fees (\$265,000), primarily due to work related to U.S. and Federal government sales of our Calmare[®] device, the management services of our current CEO, and the work of the contracted Managing Director for International Business Development.

General and administrative expenses increased to \$2,114,000 in the nine months ended September 30, 2011, compared to \$1,703,000 in the nine months ended October 31, 2010. The increase of \$411,000 is primarily due to increases in legal fees (\$583,000) associated with the legal activity relating to the former CEO challenging his termination for cause; increases in other legal fees (\$89,000); increased Board of Directors' fees and expenses associated with the increased involvement of the non-employee Chairman in CTTC operations as well as increased Board involvement with various legal actions (\$70,000); increases in audit and tax expenses (\$32,000); increase in supplies associated with the opening of the new office in North Carolina (\$22,000), an increase in contribution expenses associated with the donation of two Calmare[®] devices to a hospital in Italy (\$7,000), increased insurance costs (\$6,000), and increased costs for administering employee benefits (\$6,000). Increased sales of Calmare[®] devices have led to increases in, postage and delivery (\$20,000), banking fees (\$4,000), and in travel expenses (\$4,000) due to increased travel associated with training customers as well as increases in dues and subscriptions (\$3,000).

These increases in expenses were offset by decreases in rent and associated expenses (\$145,000), a reduction in expenses associated with being a public company including reductions due to fewer press releases being issued and the fact that the Company terminated contracts with several investor relations groups during the nine months ended October 31, 2010, so those expenses are no longer being incurred (\$108,000); a reduction in consulting fees due to the training of customers purchasing Calmare devices now being accomplished with employees (\$83,000), a reduction in marketing expenses related to the payment of consultants for marketing our Calmare device in the nine months ended October 31, 2010 which did not recur in the nine months ended September 30, 2011 (\$55,000); and reduced depreciation expense (\$23,000) due to having less property and equipment to depreciate.

In addition, during the nine months ended September 30, 2011, we incurred a reduction in the restructuring charges (\$5,000) and a recovery of bad debt (\$7,000) which had been written off during the prior year period, which when combined with the prior year bad debt expense of \$9,000 contributed a total of \$21,000 to the reduction of the increase in expenses over the nine months ended October 31, 2010.

Interest expense increased to \$29,000 in the nine months ended September 30, 2011, compared to \$5,000 in the nine months ended October 31, 2010, an increase of \$24,000 or 480% due primarily to the issuance of Notes payable and Class C Convertible Preferred Stock, during the current year, neither of which were present in the prior year period.

Financial Condition and Liquidity

Our liquidity requirements arise principally from our working capital needs, including funds needed to find and market new or existing technologies or products, and protect and enforce our intellectual property rights, if necessary. We fund our liquidity requirements with a combination of cash on hand and cash flows from operations, if any, including royalty legal awards, and sales of common stock. At September 30, 2011, we had no outstanding long-term debt.

During the quarter ended September 30, 2011, we entered into a Factoring Agreement with Versant to accelerate receivable collection and manage cash flow. Under the Factoring Agreement the Company will sell to Versant certain of the Company's accounts receivables. For those accounts receivable the Company tenders to Versant and Versant

chooses to purchase, Versant will advance 75% of the face value to the Company, and will submit a percentage of the remainder to the Company upon collection on the account. The percentage is based on the time it takes Versant to collect on the account. As part of the Factoring Agreement, the Company and Versant entered into a Security Agreement whereby the Company granted Versant a security interest in certain of the Company's assets to secure the Company's performance of the representations made with respect to the purchase of the accounts receivable. At September 30, 2011, the Company had \$465,000 in factored receivables.

Our future cash requirements depend on many factors, including results of our operations and marketing efforts, results and costs of our legal proceedings, and our equity financing. To achieve and sustain profitability, we must increase the number of distributors for our products, broaden the base of technologies for distribution, license technologies with sufficient current and long-term revenue streams, and add new licenses. Obtaining rights to new technologies, granting rights to licensees and distributors, enforcing intellectual property rights, and collecting revenue are subject to many factors, some of which are beyond our control. Although we cannot be certain that we will be successful in these efforts, we believe the combination of our cash on hand and revenue from executing our strategic plan will be sufficient to meet our obligations of current and anticipated operating cash requirements.

In fiscal 2010, the Company incorporated revenue from the sale of inventory into its revenue stream. That source of revenue is expected to continue as sales of its Calmare[®] pain therapy medical device continue to expand and other products are added to the Company's portfolio of technologies.

Cash and cash equivalents consist of demand deposits and interest earning investments with maturities of three months or less, including overnight bank deposits and money market funds. We carry cash equivalents at cost.

At September 30, 2011, the Company's balance sheet showed cash and cash equivalents of \$35,000. In addition the Company has \$750,000 of restricted cash held in escrow as a Prejudgment Remedy associated with the arbitration case involving our former Chairman, President and CEO. This is compared to \$557,000 cash and cash equivalents at December 31, 2010. The net loss of \$1,843,000 for the nine months ended September 30, 2011 contained non-cash inflow of \$93,000 and net cash inflow related to changes in assets and liabilities of \$1,041,000, resulting in cash used in operations of \$709,000. During the nine-month period ending September 30, 2011, the company issued notes payable to borrow \$200,000, paid back with interest owed one note payable (\$50,000) issued during the period, issued 175,000 shares of common stock to pay down \$217,000 in accrued liabilities, issued 19,219 shares of common stock valued at approximately \$31,000 to directors, and converted 375 shares of Class C Convertible Preferred Stock to 315,216 shares of common stock valued at approximately \$457,000 (including \$82,000 of derivative liability that was reclassified to equity upon conversion).

We currently have the benefit of using a portion of our accumulated NOLs to eliminate any future regular federal and state income tax liabilities. We will continue to receive this benefit until we have utilized all of our NOLs, federal and state. However, we cannot determine when and if we will be profitable enough to utilize the benefit of the remaining NOLs before they expire.

Going Concern

The Company incurred operating losses for the past two quarters, having produced marginal net income in the first quarter of fiscal 2011, after having incurred operating losses each quarter since fiscal 2006. During the nine month periods ended October 31, 2010 and September 30, 2011, we had a significant concentration of revenues from our Calmare® pain therapy medical device technology. We continue to seek revenue from new technologies or products to mitigate the concentration of revenues, and replace revenues from expiring licenses on other technologies.

Although we have taken steps to significantly reduce operating expenses going forward, even at these reduced spending levels, should the anticipated increase in revenue from sales of Calmare® medical devices not occur the Company may not have sufficient cash flow to fund operating expenses beyond the first quarter of calendar 2012. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

The Company's continuation as a going concern is dependent upon its developing recurring revenue streams sufficient to cover operating costs. The company does not have any significant individual cash or capital requirements in the budget going forward. During the transitional period ended December 31, 2010, the Company undertook a major reduction of its operating expenses through staff reductions and reduced office space costs. If necessary, the Company will meet anticipated operating cash requirements by further reducing costs, and/or pursuing sales of certain assets and technologies while we pursue licensing and distribution opportunities for our remaining portfolio of technologies. There can be no assurance that the Company will be successful in such efforts. Failure to develop a recurring revenue stream sufficient to cover operating expenses would negatively affect the Company's financial position.

Capital requirements

We continue to seek revenue from new technology licenses to mitigate the concentration of revenue, and replace revenue from expiring licenses. We have created a new business model for appropriate technologies that allows us to move beyond our usual royalty arrangement and share in the profits of distribution.

All purchases under \$1,000 are expensed. We expect capital expenditures to be less than \$50,000 in 2011.

Contractual Obligations and Contingencies

Because the former Chairman, President and CEO, John B. Nano, was terminated for cause in September 2010, the Company does not believe it has any remaining contractual obligations under his terminated employment agreement (See Note 12. Contingencies).

On November 22, 2010, the Company terminated our operating lease for office space and paid the landlord all existing obligations thereto. The Company then entered into a new, three-year operating lease for new, more appropriately sized office spaces. The obligations are significantly less than the previous lease, averaging \$70,000 per year for the three-year term. Under the previous lease, rent and utility obligations would have been approximately \$300,000 per year for that same period.

In January 2011, the Company entered into a two-year lease effective February 1, 2011 for additional office space for the sales and training staff in Charlotte, NC. Obligations under this lease average \$27,000 per year for the two-year term.

Contingencies. Our directors, officers, employees and agents may claim indemnification in certain circumstances.

We seek to limit and reduce our potential financial obligations for indemnification by carrying directors and officers liability insurance, subject to deductibles.

We also carry liability insurance, casualty insurance, for owned or leased tangible assets, and other insurance as needed to cover us against claims and lawsuits that occur in the ordinary course of business.

Many of our license and service agreements provide that upfront license fees, license fees and/or royalties we receive are applied against amounts that our clients or we have incurred for patent application, prosecution, issuance and maintenance costs. If we incur such costs, we expense them as incurred, and reduce our expense if we are reimbursed from future fees and/or royalties we receive. If the reimbursement belongs to our client, we record no revenue or expense.

As of September 30, 2011, CTTC and its majority-owned subsidiary, VVI, have remaining obligations, contingent upon receipt of certain revenue, to repay up to \$168,858 and \$202,124, respectively, in consideration of grant funding received in 1994 and 1995. CTTC is also obligated to pay at the rate of 7.5% of its revenue, if any, from transferring rights to certain inventions supported by the grant funds. VVI is obligated to pay at rates of 1.5% of its net sales of supported products or 15% of its revenue from licensing supported products, if any. We recognize these obligations when we receive revenue related to the grant funds. We recognized \$180 of these obligations during the quarter ended September 30, 2011.

We engage independent consultants who provide us with business development and/or evaluation services under contracts that are cancelable on certain written notice. These contracts include contingencies for potential incentive compensation earned solely on sales resulting directly from the work of the consultant. For the three and nine months ended September 30, 2011, we recorded approximately \$120,000, and \$225,000, respectively, of these contingent compensation expenses. In the three and nine months ended October 31, 2010, we incurred approximately \$14,000 and \$124,000, respectively, of such expense.

Critical Accounting Estimates

There have been no significant changes in our accounting estimates described under the caption **Critical Accounting Estimates** included in Part II, Item 7, **Management's Discussion and Analysis of Financial Condition and Results of Operations**, in our Annual report on Form 10-K for the year ended July 31, 2010.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

(a)

Evaluation of disclosure controls and procedures

Our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2011. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Act (15 U.S.C. 78a *et seq.*) is recorded, processed, summarized, and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, management concluded that our disclosure controls and procedures were effective as of September 30, 2011.

(b)

Change in Internal Controls

During the period ending September 30, 2011, there were no changes in our internal control over financial reporting during that period that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1.

Legal Proceedings

See Part I, Note 12 to the accompanying unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q.

Item 1A.

Risk Factors

We disclosed the risk factors related to our business and the market environment in our Annual Report on Form 10-K for the fiscal year ended July 31, 2010. Between July 31, 2010 and November 14, 2011, the Company has taken several actions that we believe will reduce the Company's risk. These include lowering costs through staff reductions and office relocation, developing additional sales, and obtaining additional capital.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During June 2011, the Company converted 375 shares of Class C Convertible Preferred Stock to 315,126 unregistered shares of common stock at the conversion price of \$1.19 per share of common stock. The detailed descriptions of both the conversion and the Class C Convertible Preferred Stock, which was issued in December 2010, can be found at Part I, Note 11 to the accompanying unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q.

During June 2011, the Company issued 40,000 options, with an exercise price of \$1.83 per share to its non-employee Directors in accordance with the 2011 Employees', Directors, and Consultants' Stock Option Plan. These options expire May 1, 2016.

During June 2011, the Company issued 10,000 unregistered common shares valued at \$17,800 to its non-employee Directors. These shares were issued to directors pursuant to the Company's policy for non-employee director compensation.

During May 2011, the Company issued 50,000 unregistered common shares to the Cutler Law Group to settle \$65,600 of accrued liabilities.

All of these issuances were completed without public solicitation to accredited investors in accordance with appropriate private placement exemptions.

Item 3.

Defaults Upon Senior Securities

None

Item 5.

Other Information

None.

Item 6.

Exhibits

- 31.1 Certification by the Chief Executive Officer of Competitive Technologies, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).
- 31.2 Certification by the Chief Financial Officer of Competitive Technologies, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).
- 32.1 Certification by the Chief Executive Officer of Competitive Technologies, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) (furnished herewith).
- 32.2 Certification by the Chief Financial Officer of Competitive Technologies, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) (furnished herewith).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

COMPETITIVE TECHNOLOGIES, INC.

(the registrant)

By /s/ Johnnie D. Johnson.

Johnnie D. Johnson

Chief Executive Officer,

Chief Financial Officer, Chief Accounting

Officer and Authorized Signer

November 14, 2011

INDEX TO EXHIBITS

Exhibit No.	Description
31.1	Certification by the Chief Executive Officer of Competitive Technologies, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).
31.2	Certification by the Chief Financial Officer of Competitive Technologies, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).
32.1	Certification by the Chief Executive Officer of Competitive Technologies, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) (furnished herewith).
32.2	Certification by the Chief Financial Officer of Competitive Technologies, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) (furnished herewith).

www.competitivetech.net

Page 32